Table 1

Patient characteristics

SexRace/ ethnicityHistology/tumor virus statusCSF disease# Prior therapiesAntiretroviral therapyBaseline ECOGBaseline CD4+ T cells/μLBaseline CD4+:CD8+ T cell ratio
147MWhitePeritoneal PEL, KSHV+/EBV2DOL, TAF, FTC11320.41
253MWhiteMYC rearranged GCB DLBCL, EBV4DOL, TDF, FTC02040.21
343MHispanicExtracavitary PEL, KSHV+/EBV+5Darunavir, ritonivir, DOL, TDF, FTC12280.39
453MBlackAggressive B cell lymphoma, NOS*1Darunavir, cobicistat, DOL, TAF, FTC05570.47
534FWhiteNon-GCB DLBCL, EBV+3DOL, TAF, FTC4430.34
652MBlackExtracavitary PEL†, KSHV+/EBV++2DOL, abacavir, 3TC03010.66
735MBlackPleural/pericardial PEL, KSHV+/EBV++2DOL, TAF, FTC32240.81
867FBlackNon-GCB DLBCL, EBV+4BIC, TAF, FTC13940.23
945FHispanicPBL, EBV+1BIC, TAF, FTC31070.17
1036MWhitePeritoneal PEL, KSHV+/EBV++2BIC, TAF, FTC31430.10
  • *EBV status of the tumor could not be determined in this patient.

  • †Patient 6 was treated for leptomeningeal PEL only. The patient’s systemic PEL was in complete remission at treatment initiation.

  • BIC, bictegravir; CSF, cerebrospinal fluid; DLBCL, diffuse large B cell lymphoma; DOL, dolutegravir; EBV, Epstein-Barr virus; ECOG, Eastern Cooperative Oncology Group performance score; F, cisgender female; FTC, emtricitabine; GCB, germinal center B cell; KSHV, Kaposi sarcoma herpesvirus; M, cisgender male; NOS, not otherwise specified; PBL, plasmablastic lymphoma; PEL, primary effusion lymphoma; TAF, tenofovir alafenamide fumarate; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate.